Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer